Long-term use of selective digestive decontamination in an ICU highly endemic for bacterial resistance

Crit Care. 2018 May 30;22(1):141. doi: 10.1186/s13054-018-2057-2.

Abstract

Background: We examined whether long-term use of selective digestive tract decontamination (SDD) was effective in reducing intensive care unit (ICU)-acquired infection and antibiotic consumption while decreasing colistin-, tobramycin-, and most of the antibiotic-resistant colonization rates in a mixed ICU with a high endemic level of multidrug-resistant bacteria (MDRB).

Methods: In this cohort study, which was conducted in a 30-bed medical-surgical ICU, clinical outcomes before (1 year, non-SDD group) and after (4 years) implementation of SDD were compared. ICU patients who were expected to require tracheal intubation for > 48 hours were given a standard prophylactic SDD regimen. Oropharyngeal and rectal swabs were obtained on admission and once weekly thereafter.

Results: ICU-acquired infections occurred in 110 patients in the non-SDD group and in 258 in the SDD group. A significant (P < 0.001) reduction of infections caused by MDRB (risk ratio [RR], 0.31; 95% CI, 0.23-0.41) was found after SDD and was associated with low rates of colistin- and tobramycin-resistant colonization. Colistin- and tobramycin-acquired increasing rate of ICU colonization resistance by 1000 days, adjusted by the rate of resistances at admission, was nonsignificant (0.82; 95% CI, 0.56 to 1.95; 1.13; 95% CI, 0.75 to 1.70, respectively). SDD was also a protective factor for ICU-acquired infections caused by MDR gram-negative pathogens and Acinetobacter baumannii in the multivariate analysis. In addition, a significant (P < 0.001) reduction of ventilator-associated pneumonia (VAP) (RR, 0.43; 95% CI, 0.32-0.59) and secondary bloodstream infection (BSI) (RR, 0.35; 95% CI, 0.24-0.52) was found. A decrease in antibiotic consumption was also observed.

Conclusions: Treatment with SDD during 4 years was effective in an ICU setting with a high level of resistance, with clinically relevant reductions of infections caused by MDRB, and with low rates of colistin- and tobramycin-resistant colonization with nonsignificant increasing rate of ICU colonization resistance by 1000 days, adjusted by the rate of resistances at ICU admission. In addition, VAP and secondary BSI rates were significantly lower after SDD. Notably, a decrease in antimicrobial consumption was also observed.

Keywords: Bloodstream infection; Colistin; Drug resistance; ICU-acquired infection; Multidrug-resistant pathogens; Selective digestive decontamination; Tobramycin; Ventilator-associated pneumonia.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / prevention & control
  • Cohort Studies
  • Colistin / administration & dosage
  • Colistin / therapeutic use
  • Decontamination / methods
  • Decontamination / standards*
  • Drug Resistance, Bacterial / physiology*
  • Female
  • Gastrointestinal Tract / physiopathology*
  • Humans
  • Intensive Care Units / organization & administration
  • Male
  • Middle Aged
  • Prospective Studies
  • Protective Factors
  • Spain
  • Tobramycin / administration & dosage
  • Tobramycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Tobramycin
  • Colistin